Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine,
risperidone or quetiapine in patients with schizophrenia, schizoaffective and
schizophreniform disorders under naturalistic conditions of clinical practice
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.